Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - revolade
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpf34ab6116c3c4c0c8f28f2de9888b61e
identifier: http://ema.europa.eu/identifier
/EU/1/10/612/010
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Revolade 12.5 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-f34ab6116c3c4c0c8f28f2de9888b61e
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/10/612/010
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - revolade
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
Revolade contains eltrombopag, which belongs to a group of medicines called thrombopoietin-receptor agonists. It is used to help increase the number of platelets in your blood. Platelets are blood cells that help to reduce or prevent bleeding.
ITP is caused by a low blood platelet count (thrombocytopenia). People with ITP have an increased risk of bleeding. Symptoms patients with ITP may notice include petechiae (pinpoint- sized flat round red spots under the skin), bruising, nosebleeds, bleeding gums and not being able to control bleeding if they are cut or injured.
Revolade can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment. Many people with hepatitis C have low platelet counts, not only as a result of the disease, but also due to some of the antiviral medicines that are used to treat it. Taking Revolade may make it easier for you to complete a full course of antiviral medicine (peginterferon and ribavirin).
Revolade may also be used to treat adult patients with low blood counts caused by severe aplastic anaemia (SAA). SAA is a disease in which the bone marrow is damaged, causing a deficiency of the red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).
Do not take Revolade
Check with your doctor if you think this applies to you.
Warnings and precautions Talk to your doctor before taking Revolade:
If any of these apply to you, tell your doctor before starting treatment. You should not take Revolade unless your doctor considers that the expected benefits outweigh the risk of blood clots.
Tell your doctor if any of these apply to you.
Eye examinations Your doctor will recommend that you are checked for cataracts. If you do not have routine eye-tests your doctor should arrange regular testing. You may also be checked for the occurrence of any bleeding in or around your retina (the light-sensitive layer of cells at the back of the eye).
You will need regular tests Before you start taking Revolade, your doctor will carry out blood tests to check your blood cells, including platelets. These tests will be repeated at intervals while you are taking it.
Blood tests for liver function Revolade can cause blood test results that may be signs of liver damage - an increase of some liver enzymes, especially bilirubin and alanine / aspartate transaminases. If you are taking interferon-based treatments together with Revolade to treat low platelet count due to hepatitis C, some liver problems can get worse.
You will have blood tests to check your liver function before you start taking Revolade and at intervals while you are taking it. You may need to stop taking Revolade if the amount of these substances increases too much, or if you get other signs of liver damage.
Read the information Liver problems in section 4 of this leaflet.
Blood tests for platelet count If you stop taking Revolade, your blood platelet count is likely to become low again within several days. The platelet count will be monitored, and your doctor will discuss appropriate precautions with you. A very high blood platelet count may increase the risk of blood clotting. However blood clots can also form with normal or even low platelet counts. Your doctor will adjust your dose of Revolade to ensure that your platelet count does not become too high.
Get medical help immediately if you have any of these signs of a blood clot:
Tests to check your bone marrow In people who have problems with their bone marrow, medicines like Revolade could make the problems worse. Signs of bone marrow changes may show up as abnormal results in your blood tests. Your doctor may also carry out tests to directly check your bone marrow during treatment with Revolade.
Checks for digestive bleeding If you are taking interferon-based treatments together with Revolade you will be monitored for any signs of bleeding in your stomach or intestine after you stop taking Revolade.
Heart monitoring Your doctor may consider it necessary to monitor your heart during treatment with Revolade and carry out an electrocardiogram (ECG) test.
Older people (65 years and above) There are limited data on the use of Revolade in patients aged 65 years and older. Care should be taken when using Revolade if you are aged 65 years or above.
Children and adolescents Revolade is not recommended for children aged under 1 year who have ITP. It is also not recommended for people under 18 years with low platelet counts due to hepatitis C or severe aplastic anaemia.
Other medicines and Revolade Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without prescription and vitamins.
Some everyday medicines interact with Revolade including prescription and non-prescription medicines and minerals. These include:
Talk to your doctor if you take any of these. Some of them are not to be taken with Revolade, or the dose may need adjusting, or you may need to alter the timing of when you take them. Your doctor will review the medicines you are taking, and suggest suitable replacements if necessary.
If you are also taking medicines to prevent blood clots there is a greater risk of bleeding. Your doctor will discuss this with you.
If you are taking corticosteroids, danazol, and/or azathioprine you may need to take a lower dose or to stop taking them while you are taking Revolade. Revolade with food and drink Do not take Revolade with dairy foods or drinks as the calcium in dairy products affects the absorption of the medicine. For more information, see When to take it in section 3. Pregnancy and breast-feeding Don t use Revolade if you are pregnant unless your doctor specifically recommends it. The effect of Revolade during pregnancy is not known.
Don t breast-feed while you are taking Revolade. It is not known whether Revolade passes into breast-milk.
If you are breast-feeding or planning to breast-feed, tell your doctor.
Driving and using machines Revolade can make you dizzy and have other side effects that make you less alert.
Don t drive or use machines unless you are sure you re not affected.
Revolade contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Do not change the dose or schedule for taking Revolade unless your doctor or pharmacist advises you to. While you are taking Revolade, you will be under the care of a doctor with specialist experience in treating your condition.
How much to take For ITP Adults and children (6 to 17 years) the usual starting dose for ITP is one 50 mg tablet of Revolade a day. If you are of East-/Southeast-Asian origin you may need to start at a lower dose of 25 mg.
Children (1 to 5 years) the usual starting dose for ITP is one 25 mg tablet of Revolade a day.
For hepatitis C Adults - the usual starting dose for hepatitis C is one 25 mg tablet of Revolade a day. If you are of East-/Southeast-Asian origin you will start on the same 25 mg dose.
For SAA Adults - the usual starting dose for SAA is one 50 mg tablet of Revolade a day. If you are of East- /Southeast-Asian origin you may need to start at a lower dose of 25 mg.
Revolade may take 1 to 2 weeks to work. Based on your response to Revolade your doctor may recommend that your daily dose is changed.
How to take the tablets Swallow the tablet whole, with some water.
When to take it
Make sure that
you don t consume any of the following:
If you do, the medicine will not be properly absorbed into your body.
For more advice about suitable foods and drinks, talk to your doctor.
If you take more Revolade than you should Contact a doctor or pharmacist immediately. If possible show them the pack, or this leaflet. You will be monitored for any signs or symptoms of side effects and given appropriate treatment immediately.
If you forget to take Revolade Take the next dose at the usual time. Do not take more than one dose of Revolade in one day.
If you stop taking Revolade Don t stop taking Revolade without talking to your doctor. If your doctor advises you to stop treatment, your platelet count will then be checked each week for four weeks. See also Bleeding or bruising after you stop treatment in section 4. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Symptoms needing attention: see a doctor People taking Revolade for either ITP or low blood platelet counts due to hepatitis C could develop signs of potentially serious side effects. It is important to tell a doctor if you develop these symptoms.
NO dairy products, antacids or mineral supplements Take Revolade For 4 hours before you
take Revolade... ... and for 2 hours after Higher risk of blood clots Certain people may have a higher risk of blood clots, and medicines like Revolade could make this problem worse. The sudden blocking of a blood vessel by a blood clot is an uncommon side effect and may affect up to 1 in 100 people.
Get medical help immediately if you develop signs and symptoms of a blood clot, such as:
Liver problems Revolade can cause changes that show up in blood tests, and may be signs of liver damage. Liver problems (increased enzymes showing up in blood tests) are common and may affect up to 1 in 10 people. Other liver problems are uncommon and may affect up to 1 in 100 people.
If you have either of these signs of liver problems:
tell your doctor immediately.
Bleeding or bruising after you stop treatment Within two weeks of stopping Revolade, your blood platelet count will usually drop back down to what it was before starting Revolade. The lower platelet count may increase the risk of bleeding or bruising. Your doctor will check your platelet count for at least 4 weeks after you stop taking Revolade.
Tell your doctor if you have any bleeding or bruising after stopping Revolade.
Some people have bleeding in the digestive system after they stop taking peginterferon, ribavirin, and Revolade. Symptoms include:
Tell your doctor immediately if you have any of these symptoms.
The following side effects have been reported to be associated with treatment with Revolade in adult patients with ITP:
Very common side effects These may affect more than 1 in 10 people:
Very common side effects that may show up in blood tests:
Common side effects These may affect up to 1 in 10 people:
Common side effects that may show up in blood test:
Uncommon side effects These may affect up to 1 in 100 people:
Uncommon side effects that may show up in laboratory tests:
The following additional side effects have been reported to be associated with treatment with Revolade in children (aged 1 to 17 years) with ITP: If these side effects become severe, please tell your doctor, pharmacist or nurse.
Very common side effects These may affect more than 1 in 10 children:
Common side effects These may affect up to 1 in 10 children:
The following side effects have been reported to be associated with treatment with Revolade in combination with peginterferon and ribavirin in patients with HCV:
Very common side effects These may affect more than 1 in 10 people:
Very common side effects that may show up in blood tests:
Common side effects These may affect up to 1 in 10 people:
Uncommon side effects These may affect up to 1 in 100 people:
The following side effects have been reported to be associated with treatment with Revolade in patients with severe aplastic anaemia (SAA): If these side effects become severe, please tell your doctor, pharmacist or nurse.
Very common side effects These may affect more than 1 in 10 people.
Very common side effects that may show up in the blood tests
Common side effects These may affect up to 1 in 10 people.
Common side effects that may show up in the blood tests
Side effects with frequency not known Frequency cannot be estimated from the available data
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the blister.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Revolade contains The active substance in Revolade is eltrombopag.
12.5 mg film-coated tablets Each film-coated tablet contains eltrombopag olamine equivalent to 12.5 mg eltrombopag.
25 mg film-coated tablets Each film-coated tablet contains eltrombopag olamine equivalent to 25 mg eltrombopag.
50 mg film-coated tablets Each film-coated tablet contains eltrombopag olamine equivalent to 50 mg eltrombopag.
75 mg film-coated tablets Each film-coated tablet contains eltrombopag olamine equivalent to 75 mg eltrombopag.
The other ingredients are: hypromellose, macrogol 400, magnesium stearate, mannitol (E421), microcrystalline cellulose, povidone, sodium starch glycolate, titanium dioxide (E171).
Revolade 12.5 mg and 25 mg film-coated tablets also contain polysorbate 80 (E433).
Revolade 50 mg film-coated tablets also contain iron oxide red (E172) and iron oxide yellow (E172).
Revolade 75 mg film-coated tablets also contain iron oxide red (E172) and iron oxide black (E172).
What Revolade looks like and contents of the pack Revolade 12.5 mg film-coated tablets are round, biconvex, white, debossed with GS MZ1 and 12.5
on one side.
Revolade 25 mg film-coated tablets are round, biconvex, white, debossed with GS NX3 and 25 on one side.
Revolade 50 mg film-coated tablets are round, biconvex, brown, debossed with GS UFU and 50 on one side.
Revolade 75 mg film-coated tablets are round, biconvex, pink, debossed with GS FFS and 75 on one side.
They are supplied in aluminum blisters in a carton containing 14 or 28 film-coated tablets and multipacks containg 84 (3 packs of 28) film-coated tablets).
Not all pack sizes may be available in your country.
Marketing authorisation holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland
Manufacturer Lek d.d Verovskova Ulica Ljubljana 1Slovenia
Novartis Pharmaceutical Manufacturing LLC Verovskova Ulica Ljubljana 1Slovenia
Novartis Farmac utica SA Gran Via de les Corts Catalanes, 08013 Barcelona Spain
Novartis Pharma GmbH Roonstra e D-90429 Nuremberg Germany
Glaxo Wellcome S.A. Avenida de Extremadura 3 09400 Aranda de Duero Burgos Spain
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16
Novartis Bulgaria EOOD : +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0
Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20
Novartis (Hellas) A.E.B.E. : +30 210 281 17 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Novartis Farmac utica, S.A. Tel: +34 93 306 42 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133
Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-f34ab6116c3c4c0c8f28f2de9888b61e
Resource Composition:
Generated Narrative: Composition composition-en-f34ab6116c3c4c0c8f28f2de9888b61e
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/10/612/010status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - revolade
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpf34ab6116c3c4c0c8f28f2de9888b61e
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpf34ab6116c3c4c0c8f28f2de9888b61e
identifier:
http://ema.europa.eu/identifier
/EU/1/10/612/010type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Revolade 12.5 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en